Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02091193 · ClinicalTrials.gov registry record

Effects of Krill Oil on Endothelial Function in Patients With Type 2 Diabetes Mellitus

A clinical trial, sponsored by Danbury Hospital.

Completed
Registry status
47
Enrollment target

NCT02091193: Completed study, sponsored by Danbury Hospital.

NCT02091193 is a clinical trial that has completed, run by Danbury Hospital. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02091193 has completed, sponsored by Danbury Hospital.

COMPLETED
Registry status
47 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the effects of krill oil supplementation in patients with Type 2 diabetes mellitus on heart health and laboratory diabetic measurements. Patients who enroll in this study will be asked to visit the Western Connecticut Health Network Biomedical Research Institute on 3 separate occasions: for baseline testing, after 4 weeks of supplementing with krill oil, and after 4 weeks of supplementing with a placebo. Patients will be randomized into one of two groups to determine the order in which they receive the supplement and placebo. Every patient will receive both the krill oil and the placebo, but both the coordinator and the patient are blinded to which is which. At each visit, participants will undergo a non-invasive test which measures the function of the inner lining of blood vessels and they will also have blood drawn. Fasting is required before each appointment. The blood drawn is used to measure their Hemoglobin A1C, Glucose, HDL, LDL, total cholesterol, C-peptide and total antioxidant capacity. Risks to taking krill oil supplements are likely to include bad breath, heartburn, fishy taste, upset stomach, nausea, loose stools, gas, and bloating. Risks of EndoPAT testing are not permanent and may include pain, numbness, tingling, redness, and bruising at the site of the blood pressure cuff. Risks that are associated with drawing blood may include redness, swelling, pain or discomfort, bruising at the site of the needle stick, or in very rare cases, infection at the needle site. To minimize these risks, trained technologists and phlebotomists will be used for all procedures. This is not a treatment option; while involved in this study all participants will continue their regular treatment for Type 2 diabetes mellitus (as well as any other applicable conditions).

Interventions

  • DIETARY_SUPPLEMENT Krill Oil (Supplement A)
  • DIETARY_SUPPLEMENT Placebo (Supplement B)

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2012-03
Est. Completion 2013-12
Danbury Hospital

7 total trials

What the finished NCT02091193 record still lists

NCT02091193 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 47 participants, a relatively small participant target.

The record links to 0 conditions, and to 2 interventions - of which Krill Oil (Supplement A) is the first listed.

NCT02091193 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02091193 about?

NCT02091193 is a clinical study titled "Effects of Krill Oil on Endothelial Function in Patients With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the effects of krill oil supplementation in patients with Type 2 diabetes mellitus on heart health and laboratory diabetic measurements. Patients who enroll in this study will be asked to visit the Western Connecticut Health Network Biomedical Research Insti...

What is the current status of trial NCT02091193?

This trial is currently completed. The enrollment target is 47 participants. The study started on 2012-03. Estimated completion is 2013-12.

What interventions are being tested in trial NCT02091193?

The interventions under investigation include: Krill Oil (Supplement A) (DIETARY_SUPPLEMENT), Placebo (Supplement B) (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02091193?

This trial is sponsored by Danbury Hospital, which has 7 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03313011 · 47 participants

    The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech

  • NCT03467516 · 47 participants · Phase 2

    Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

  • NCT03886662 · 47 participants · Phase 1

    A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

  • NCT04013802 · 47 participants · Phase 1

    TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02091193, the US trial registry maintained by the National Library of Medicine. NCT02091193 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.